Abstract
Focal adhesion kinase (FAK) is a non-receptor tryosine kinase that plays a vital role in tumor cell survival, proliferation and migration. It has been shown that inhibiting the activity of FAK may result in impeding tumor cells invasion and growth. There are several small molecule FAK inhibitors which have been developed with outstanding FAK inhibitory activity. And most of the small molecules are nitrogen-containing aromatic compounds. This review describes the chemical structure characteristics and activity of current small molecule FAK inhibitors that aims to serve as a future reference for the development of potential FAK inhibitors.
Keywords: Cancer, chemical structure, FAK inhibitors.
Anti-Cancer Agents in Medicinal Chemistry
Title:Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors
Volume: 16 Issue: 8
Author(s): Fang-Yuan Cao, Xiao-Ping Zhou, Jing Su, Xiao-Hong Yang, Feng-Hui Mu, Jia-Yi Shen and Wei Sun
Affiliation:
Keywords: Cancer, chemical structure, FAK inhibitors.
Abstract: Focal adhesion kinase (FAK) is a non-receptor tryosine kinase that plays a vital role in tumor cell survival, proliferation and migration. It has been shown that inhibiting the activity of FAK may result in impeding tumor cells invasion and growth. There are several small molecule FAK inhibitors which have been developed with outstanding FAK inhibitory activity. And most of the small molecules are nitrogen-containing aromatic compounds. This review describes the chemical structure characteristics and activity of current small molecule FAK inhibitors that aims to serve as a future reference for the development of potential FAK inhibitors.
Export Options
About this article
Cite this article as:
Cao Fang-Yuan, Zhou Xiao-Ping, Su Jing, Yang Xiao-Hong, Mu Feng-Hui, Shen Jia-Yi and Sun Wei, Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (8) . https://dx.doi.org/10.2174/1871520616666151116122355
DOI https://dx.doi.org/10.2174/1871520616666151116122355 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Alteration of Isocitrate Dehydrogenase Following Acute Ischemic Injury as a Means to Improve Cellular Energetic Status in Neuroadaptation
CNS & Neurological Disorders - Drug Targets The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
Current Medicinal Chemistry Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Neurovascular Signals Suggest a Propagation Mechanism for Endogenous Stem Cell Activation Along Blood Vessels
CNS & Neurological Disorders - Drug Targets Mechlorethamine based Drug Structures for Intervention of Central Nervous System Tumors
Central Nervous System Agents in Medicinal Chemistry Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Current Cancer Drug Targets Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Intracellular Signaling Pathways Modulated by Phenolic Compounds: Application for New Anti-Inflammatory Drugs Discovery
Current Medicinal Chemistry Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Intra-arterial Temozolomide, Osmotic Blood-brain Barrier Disruption and Radiotherapy in a Rat F98-Glioma Model
Clinical Cancer Drugs Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Lessons Learned from the Irinotecan Metabolic Pathway
Current Medicinal Chemistry Cytosine Methyltransferases as Tumor Markers
Current Genomics Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism